UNSPSC 51191913: Acitretin

This classification denotes a retinoic acid agent with the molecular formula C21H26O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LCH760E9T7, chemically known as 2,4,6,8-nonatetraenoic acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, (all-e)- but generally known as acitretin, which bears US NIH Compound Identifier 5284513. European Medicines Agency schedules Acitretin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05240MIG.

UNSPSC 51191913 Acitretin is a Commodity code for a specific pharmaceutical product, but recent state and local procurement activity under this code shows minimal relevant solicitations. The one pharmaceutical-related opportunity in the recent record—the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products—casts a broad net across many drug products and is not specific to acitretin. The second recent opportunity tagged under this code, the City of Meriden's bid for sodium bisulfite chemical supply for water treatment, falls entirely outside the pharmaceutical scope and appears to be a tagging mismatch. State and local health departments, correctional facilities, state agencies providing medical services, and cooperative purchasing organizations would be the typical issuing bodies for pharmaceutical procurement, but the current record does not demonstrate active solicitation of acitretin specifically.

The geographic distribution of recent activity is limited. Minnesota and Connecticut appear in the current opportunities block, though only Minnesota's cooperative pharmaceutical procurement is pharmaceutical-related in substance. No other states show acitretin-specific opportunities in the recent record. The MMCAP RFP (posted January 20, 2026, with a March 26, 2026 response deadline) represents the only state-and-local-level pharmaceutical demand signal, but it targets generic multi-source drugs and OTC products distributed through authorized wholesalers rather than acitretin as a named line item. Business development professionals should monitor whether acitretin appears in future MMCAP product schedules or whether state Medicaid agencies, state health systems, or state prison health services issue dedicated solicitations naming the product, as current activity does not support active pursuit under this code.